Amicus Therapeutics to Present at Goldman Sachs US Emerging / SMID Cap Growth Conference

CRANBURY, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company at the forefront of rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Goldman Sachs US Emerging / SMID Cap Growth Conference in New York, NY on Thursday, November 19, 2015 at 1:50 p.m. ET.

A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other lysosomal storage disorders.

FOLD–G

CONTACT: Investors/Media:
         Amicus Therapeutics
         Sara Pellegrino
         Director, Investor Relations
         [email protected]
         (609) 662-5044

         Media:
         Pure Communications
         Dan Budwick
         [email protected]
         (973) 271-6085

Source: Amicus Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• 1847 Holdings Signs Letter of Intent to Buy Leader in Millwork, Cabinetry and Door Manufacturing, Expands Its Presence in Growing Market
• How I Got Here: Jon Hixson
• Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s